OverviewSuggest Edit

Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics. It specializes in the field of amino acid metabolism to treat rare genetic diseases and cancer.
TypePublic
Founded2013
HQAustin, TX, US
Websiteaeglea.com

Latest Updates

Employees (est.) (Dec 2019)76(+2%)
Revenue (FY, 2020)$0
Share Price (Nov 2021)$7(-3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Aeglea

Anthony Quinn

Anthony Quinn

President & Chief Executive Officer, Director
Michael C. Hanley

Michael C. Hanley

Chief Commercial Officer
Eric Bradford

Eric Bradford

Chief Development Officer
Scott W. Rowlinson

Scott W. Rowlinson

Vice President of Research
Joseph E. Tyler

Joseph E. Tyler

Vice President of Manufacturing
Leslie Sloan

Leslie Sloan

Chief Operating Officer
Show more

Aeglea Office Locations

Aeglea has an office in Austin
Austin, TX, US (HQ)
805 Las Cimas Pkwy #100
Show all (1)

Aeglea Financials and Metrics

Aeglea Revenue

USD

Net income (Q1, 2021)

(18.2m)

EBIT (Q1, 2021)

(18.2m)

Market capitalization (12-Nov-2021)

359.5m

Closing stock price (12-Nov-2021)

7.0

Cash (31-Mar-2021)

80.2m

EV

284.6m
Aeglea's current market capitalization is $359.5 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.2m3.9m

Revenue growth, %

(25%)(100%)

General and administrative expense

10.1m12.6m15.7m21.8m

R&D expense

22.8m36.7m64.6m59.6m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.5m2.4m

General and administrative expense

2.9m2.9m3.3m3.3m3.8m4.3m4.5m4.7m5.7m6.4m

R&D expense

6.9m9.1m8.9m14.4m14.8m17.8m14.6m16.9m12.5m11.9m

Operating expense total

9.8m12.0m12.2m17.7m18.6m22.1m19.0m21.6m18.1m18.2m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

12.8m22.5m19.3m90.1m

Accounts Receivable

3.1m

Prepaid Expenses

1.6m2.2m2.6m3.5m

Current Assets

55.0m76.7m74.5m149.8m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

10.8m20.6m14.5m85.6m25.4m24.5m12.6m65.7m54.2m80.2m

Accounts Receivable

3.4m4.3m2.4m21.5m

Prepaid Expenses

2.0m2.4m3.2m3.1m4.4m3.9m5.3m4.1m4.4m3.3m

Current Assets

48.8m78.9m70.4m126.8m109.9m92.6m54.3m161.9m144.4m151.4m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(27.2m)(44.3m)(78.3m)(80.9m)

Depreciation and Amortization

249.0k293.0k418.0k996.0k

Accounts Payable

164.0k239.0k2.6m(544.0k)

Cash From Operating Activities

(24.6m)(32.2m)(65.7m)(75.8m)
Quarterly
USDFY, 2017

Revenue/Employee

127.0k

Financial Leverage

1.1 x
Show all financial metrics

Aeglea Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Aeglea Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Aeglea Online and Social Media Presence

Embed Graph

Aeglea Company Culture

  • Compensation

    A+

    100/100

Learn more on Comparably

Aeglea News and Updates

Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third...

Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics

AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that seven abstracts will be presented...

Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its first quarter 2021 financial...

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announced the license and supply agreement for pegzilarginase, a no…

Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Sara Brownstein to its board of directors. Ms. Brownstein serves as a p…

Aeglea BioTherapeutics Announces Transition of Chief Financial Officer

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company's chief financial officer, Charles N. York II, will be leaving the company…
Show more

Aeglea Blogs

Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors

AUSTIN, Texas , Dec. 17, 2020 /PRNewswire/ --  Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the appointment of Alison

Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference

Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference Content Import Tue, 11/24/2020 - 16:41 Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference 11/24/20 This release is a backfill from a News…

Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences

AUSTIN, Texas , Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in fireside

Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights

Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177   Continued Progress in Arginase 1 Deficiency Patient Identification and Engagement Efforts AUSTIN, Texas , Nov. 5, 2020 /PRNewswire/ --  Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings

AUSTIN, Texas , Oct. 5, 2020 /PRNewswire/ --  Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the presentation of a poster on

Aeglea BioTherapeutics to Participate in September Investment Conferences

AUSTIN, Texas , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in
Show more

Aeglea Frequently Asked Questions

  • When was Aeglea founded?

    Aeglea was founded in 2013.

  • Who are Aeglea key executives?

    Aeglea's key executives are Anthony Quinn, Michael C. Hanley and Eric Bradford.

  • How many employees does Aeglea have?

    Aeglea has 76 employees.

  • Who are Aeglea competitors?

    Competitors of Aeglea include Horizon Therapeutics, Erytech Pharma and Embera NeuroTherapeutics.

  • Where is Aeglea headquarters?

    Aeglea headquarters is located at 805 Las Cimas Pkwy #100, Austin.

  • Where are Aeglea offices?

    Aeglea has an office in Austin.

  • How many offices does Aeglea have?

    Aeglea has 1 office.